Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward
Advancing TDM of oral targeted anticancer drugs requires finding the right drugs, the right patients, the right drug exposure targets, the right sampling methods, and the right evidence. Addressing these issues can facilitate clinical implementation and ensure that TDM can be applied for both older and newly approved oral targeted anticancer drugs.
Authors
- Alwin D. R. Huitema (ORCID: https://orcid.org/0000-0003-1939-4639)
- Neeltje Steeghs (ORCID: https://orcid.org/0000-0003-2989-2279)
- Stijn L.W. Koolen (ORCID: https://orcid.org/0000-0002-0973-7530)
- Ron H.J. Mathijssen (ORCID: https://orcid.org/0000-0001-5667-5697)
- Maud B. A. van der Kleij (ORCID: https://orcid.org/0009-0008-8492-8039)
- Karolijn W. M. Groot Beumer
Institutions
- Erasmus MC (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Oncode Institute (NL)
- Erasmus MC Cancer Institute (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1097/ftd.0000000000001391
- Citations
- 1
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.81